<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02209896</url>
  </required_header>
  <id_info>
    <org_study_id>CP-04-001</org_study_id>
    <nct_id>NCT02209896</nct_id>
  </id_info>
  <brief_title>BlueWind Reprieve System for the Treatment of PNP</brief_title>
  <official_title>Safety and Performance of the BlueWind Medical Reprieve System for the Treatment of Patients With Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BlueWind Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BlueWind Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BlueWind Reprieve system is a neurostimulator consisting of an Implant and external&#xD;
      components.&#xD;
&#xD;
      The system is intended for home care use. The chronic pain treatment is achieved by an&#xD;
      electrical stimulation of peripheral nerve fibers. The stimulation is set so that it&#xD;
      generates paresthesia in the stimulated area (e.g. foot), reducing the pain sensation and&#xD;
      improving the quality of life for the patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of serious adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence of serious adverse events (system and/or procedure related events)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain assessment</measure>
    <time_frame>6 months post system activation</time_frame>
    <description>Pain assessment by Visual Analogue Scale (VAS) as compared to baseline at 6 months post activation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical success defined as the effect of the Reprieve System on patient's symptoms</measure>
    <time_frame>6 months post system activation</time_frame>
    <description>Measurements include:&#xD;
SF-McGill pain Questionnaire Pain related medication consumption/day Quality of life questionnaire SF-36 Health survey and safety</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Peripheral Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>BlueWind Reprieve System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Reprieve implant will be implanted for eligible patients. Implant parameters settings will be set according to patient's sensations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Reprieve system</intervention_name>
    <description>BlueWind Medical neurostimulator for the treatment of neuropathic pain</description>
    <arm_group_label>BlueWind Reprieve System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
          -  Male or female aged 18 - 80.&#xD;
&#xD;
          -  Patient agrees to attend all follow-up evaluations and is willing to completely and&#xD;
             accurately fill out pain questionnaires.&#xD;
&#xD;
          -  Diagnosis of chronic neuropathic pain due to peripheral neuropathy.&#xD;
&#xD;
          -  Documented pain attributed to neuropathy for at least 6 months.&#xD;
&#xD;
          -  Pain intensity with an average daily VAS score of at least 6, demonstrated by 3&#xD;
             ratings per day across 7 days.&#xD;
&#xD;
          -  Patient refractory to conservative treatments including pain medication, for at least&#xD;
             6 months.&#xD;
&#xD;
          -  Stable pain medication for at least 4 weeks prior to study enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in another study with any investigational drug or device within&#xD;
             the past 90 days.&#xD;
&#xD;
          -  Any active implant (cardiac or other).&#xD;
&#xD;
          -  Any metal implant in the area of BlueWind device implantation site.&#xD;
&#xD;
          -  Current pregnancy or attempting to get pregnant (female patient).&#xD;
&#xD;
          -  Any clinically significant neurologic disorders (except PNP).- Any clinically&#xD;
             significant or unstable medical or psychiatric condition that would affect the&#xD;
             patient's ability to participate in the study.&#xD;
&#xD;
          -  Patients with severe or unstable cardiovascular, pulmonary, gastrointestinal,&#xD;
             hematological, hepatic, renal or endocrine diseases.&#xD;
&#xD;
          -  Severe peripheral vascular disease that may cause intermittent claudication or&#xD;
             ischemic ulcers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Dabby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wolfson Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Health care campus</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>August 3, 2014</study_first_submitted>
  <study_first_submitted_qc>August 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2014</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Neuropathic Pain</keyword>
  <keyword>PNP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

